Sep 10, 2026 08:30AM
Aug 13, 2026 05:12PM
Aug 13, 2026 05:12PM
Jul 13, 2026 06:59AM
Jul 13, 2026 06:59AM
Jun 1, 2026 06:59AM
Jun 1, 2026 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype
Feb 17, 2026 05:31PM
Feb 17, 2026 07:00AM
Feb 17, 2026 06:59AM
Dec 11, 2025 06:59AM
Dec 11, 2025 06:59AM
Oct 27, 2025 06:59AM
Oct 27, 2025 06:59AM Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
Oct 1, 2025 01:20PM
Aug 4, 2025 04:16PM
Aug 4, 2025 04:16PM
Jul 21, 2025 07:00AM
Jul 21, 2025 06:59AM
Apr 8, 2025 03:39PM
Apr 8, 2025 03:36PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Defi
Mar 7, 2025 06:59AM
Mar 7, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 6, 2025 06:59AM
Jan 31, 2025 06:59AM
Jan 31, 2025 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular
Dec 11, 2024 09:44AM
Oct 31, 2024 06:59AM
Sep 27, 2024 08:05AM
Sep 27, 2024 06:07AM
Sep 23, 2024 07:28AM
Aug 28, 2024 02:01AM
Aug 21, 2024 07:00AM Bristol-Myers Squibb (BMY) Announces FDA sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Aug 21, 2024 06:59AM
Jul 26, 2024 06:59AM
Jul 23, 2024 06:35AM
Jun 17, 2024 09:45AM
May 21, 2024 06:59AM
May 21, 2024 06:59AM
May 6, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Application for Subcutaneous Nivolumab
May 6, 2024 06:59AM
Apr 25, 2024 06:59AM
Apr 25, 2024 05:22AM
Apr 8, 2024 11:31AM
Apr 8, 2024 11:30AM
Apr 1, 2024 07:31AM
Apr 1, 2024 07:30AM Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA
Mar 28, 2024 04:07PM

15,802 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All